Patents by Inventor Le T. Duong

Le T. Duong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Composition and Methods for Treating Chronic Kidney Disease
    Publication number: 20190307735
    Abstract: This invention relates to the treatment of chronic kidney disease, including diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), nephrotic syndrome, non-diabetic chronic kidney disease, renal fibrosis or acute kidney injury by the administration of an RGD mimetic integrin receptor antagonist, either as a single agent or in combination with other agents.
    Type: Application
    Filed: June 18, 2019
    Publication date: October 10, 2019
    Applicant: MERCK SHARP & DOHME CORP
    Inventors: Jason M. Cox, Lijun Ma, Xiaoyan Zhou, Robin E. Haimbach, Paul J. Coleman, Haihong Zhou, David E. Kelley, Selwyn Aubrey Stoch, Le T. Duong, Maarten Hoek
  • Compositions Methods for Treating Chronic Kidney Disease
    Publication number: 20180110762
    Abstract: This invention relates to the treatment of chronic kidney disease, including diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), nephrotic syndrome, non-diabetic chronic kidney disease, renal fibrosis or acute kidney injury by the administration of an RGD mimetic integrin receptor antagonist, either as a single agent or in combination with other agents.
    Type: Application
    Filed: March 24, 2016
    Publication date: April 26, 2018
    Applicant: Merck Sharp & Dohme Corp
    Inventors: Jason M. COX, Lijun MA, Xiaoyan ZHOU, Robin E. HAIMBACH, Paul J. COLEMAN, Haihong ZHOU, David E. KELLEY, Selwyn Aubrey STOCH, Le T. DUONG, Maarten HOEK
  • Integrin targeting agents and in-vivo and in-vitro imaging methods using the same
    Patent number: 9694089
    Abstract: The invention provides a family of agents that target integrins, which can be used as imaging agents and/or therapeutic agents. The agents can be used to image angiogenesis, inflammation or other physiological processes in a subject.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: July 4, 2017
    Assignees: Visen Medical, Inc., Merck Sharp & Dohme Corp.
    Inventors: Milind Rajopadhye, Guojie Ho, Bohumil Bednar, Le T. Duong, Paul J. Coleman
  • INTEGRIN TARGETING AGENTS AND IN-VIVO AND IN-VITRO IMAGING METHODS USING THE SAME
    Publication number: 20140170066
    Abstract: The invention provides a family of agents that target integrins, which can be used as imaging agents and/or therapeutic agents. The agents can be used to image angiogenesis, inflammation or other physiological processes in a subject.
    Type: Application
    Filed: February 24, 2014
    Publication date: June 19, 2014
    Applicants: Merck & Co., Inc., Visen Medical, Inc.
    Inventors: Milind Rajopadhye, Guojie Ho, Bohumil Bednar, Le T. Duong, Paul J. Coleman
  • Integrin targeting agents and in-vivo and in-vitro imaging methods using the same
    Patent number: 8685370
    Abstract: The invention provides a family of agents that target integrins, which can be used as imaging agents and/or therapeutic agents. The agents can be used to image angiogenesis, inflammation or other physiological processes in a subject.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: April 1, 2014
    Assignees: Visen Medical, Inc., Merck & Co., Inc.
    Inventors: Milind Rajopadhye, Guojie Ho, Bohumil Bednar, Le T. Duong, Paul J. Coleman
  • INTEGRIN TARGETING AGENTS AND IN-VIVO AND IN-VITRO IMAGING METHODS USING THE SAME
    Publication number: 20110165075
    Abstract: The invention provides a family of agents that target integrins, which can be used as imaging agents and/or therapeutic agents. The agents can be used to image angiogenesis, inflammation or other physiological processes in a subject.
    Type: Application
    Filed: March 13, 2009
    Publication date: July 7, 2011
    Inventors: Milind Rajopadhye, Guojie Ho, Bohumil Bednar, Le T. Duong, Paul J. Coleman
  • Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist
    Publication number: 20020040039
    Abstract: The present invention provides for methods for treating or preventing an inflammatory disease or condition in a mammalian patient in need of such treatment comprising administering to said patient a cyclooxygenase-2 specific inhibitor in combination with an &agr;V&bgr;3, &agr;V&bgr;5 and/or &agr;V&bgr;6 integrin receptor antagonist in an amount effective to treat or prevent the inflammatory disease or condition. The present invention also provides for pharmaceutical compositions for the treatment or prevention of an inflammatory disease or condition. Further, the invention provides for the manufacture of a medicament useful in the treatment or prevention of an inflammatory disease or condition.
    Type: Application
    Filed: September 18, 2001
    Publication date: April 4, 2002
    Inventors: George Hartman, Mark Duggan, Gideon Rodan, Sevgi B. Rodan, Le T. Duong, Donald B. Kimmel
  • Mouse integrin subunits
    Patent number: 6057113
    Abstract: The full-length mouse .beta.3 integrin has been cloned and sequenced. A new form of .beta.3 integrin (.beta.3-trunc also been cloned and sequenced.
    Type: Grant
    Filed: December 22, 1998
    Date of Patent: May 2, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Le T. Duong, Gideon A. Rodan, Elka M. Nutt
  • Nucleic acids encoding a truncated mouse .beta. integrin subunit
    Patent number: 5895754
    Abstract: The full-length mouse .beta.3 integrin has been cloned and sequenced. A new form of .beta.3 integrin (.beta.3 trunc ) has also been cloned and sequenced.
    Type: Grant
    Filed: October 29, 1997
    Date of Patent: April 20, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Le T. Duong, Gideon A. Rodan, Elka M. Nutt
  • Humoral hypercalcemic factor antagonists modified at position 13 by biotin
    Patent number: 5087561
    Abstract: The present invention relates to the use of peptide analogues as inhibitors of their respective naturally occurring peptides. The structure of the peptide hormone analogues is exemplified by human humoral hypercalcemic factor (hHCF), wherein Lys.sup.13 or Lys.sup.11 is modified on the epsilon-amino group by biotin so as to produce HCF analogues which can inhibit the action of HCF.
    Type: Grant
    Filed: June 28, 1990
    Date of Patent: February 11, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Michael Rosenblatt, Michael Chorev, Eliahu Roubini, Ruth F. Nutt, Le T. Duong